Advertisement


Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab

2024 ASCO Annual Meeting

Advertisement

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (Abstract TPS7089).  



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
[Inaudible 00:00:08] is a standard of care option for patients with CLL, SLL, who have relapsed after at least one line of prior therapy. However, there is an unmet need for more effective treatments. Bruton tyrosine kinase, BTK, plays an important role in the pathogenesis of CLL. Nemtabrutinib is a BTK inhibitor that targets both wild-type and C-481 mutant forms of BTK, in the ongoing BELLWAVE-001 study, nemtabrutinib demonstrates manageable safety and durable anti-tumor activity in patients with refractory relapse, CLL, SLL, with and without C-481 mutations. The randomized open-label phase III BELLWAVE zero-tense study is designed to evaluate the efficacy and safety of nemtabrutinib plus venetoclax versus VR as a second line or later treatment for patients with RR CLL, SLL. Eligible patients are aged more than 18 years with active refractory relapse CLL, SLL after at least one line on prior therapy per IW-CLL 2018 criteria, and equal performance status of zero to two approximately 720 patients will be enrolled in two parts. Part one is an open-label, non-randomized dose escalation and confirmation phase to evaluate safety, and determine the optimal dose of nemtabrutinib plus venetoclax. Part one will enroll 30 patients to establish the dose of nemtabrutinib, using a modified toxicity probability interval design. Patients will receive nemtabrutinib at two dose levels. 45 milligram per day parallel Q-day, starting dose. Escalating to six five milligram parallel Q-day for 28 days, followed by nemtabrutinib plus venetoclax ramp up over four weeks. Part two is an open-label parallel group randomized phase comparing the efficacy and safety of nemtabrutinib plus venetoclax with VR. In part two, approximately 690 patients will be randomly assigned one-to-one to receive either nemtabrutinib at recommended dose for 28 days, followed by the nemtabrutinib plus venetoclax, or venetoclax plus rituximab. Study treatment will continue for approximately two years, or until an acceptable toxicity, disease progression, or other discontinuation criteria are met. Randomization will be certified by BTKC-481 mutation status, geographic region, and risk group. The primary endpoint for part two is progression free survival by Blinded Independent Central Review, BICR, per IWCLL 2018 criteria. Secondary endpoints for part two are: Undetectable, minimal residual disease in bone marrow at month 14 by central laboratory assessment, objective response rate and duration of response by BICR per IWCLL 2018 criteria, Overall survival and safety. Exploratory endpoints are overall response rate, including partial response with lymphocytosis, pharmacokinetics, and heart-related quality of life. Recruitment is ongoing.

Related Videos

Clifford A. Hudis, MD, and Karen E. Knudsen, MBA: An ASCO–American Cancer Society Partnership to Benefit Patients

Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO), and Karen E. Knudsen, MBA, CEO of the American Cancer Society, discuss a newly launched collaboration between the organizations to make it simpler for patients to find authoritative cancer information online. The effort creates one of the largest and most comprehensive online resources for credible cancer information, available for free to the public on cancer.org.

 

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).

 

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Recruiting for the CELESTIAL-TNCLL Study

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses an ongoing phase III study of the BCL2 inhibitor sonrotoclax plus zanubrutinib vs venetoclax and obinutuzumab for patients with treatment-naive chronic lymphocytic leukemia. The investigators are recruiting internationally (see NCT06073821; Abstract TPS7087).

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable stage III melanoma compared with adjuvant nivolumab (LBA2)

Gynecologic Cancers

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).

Advertisement

Advertisement




Advertisement